Save time and jump to the most important pieces.
Experienced Drug Developer Brings Over 15 Years of Clinical Development Industry Knowledge across Multiple Therapeutic Areas and Modalities TEL AVIV, Israel, Jan. 4, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer. Dr. Rachmilewitz will report to the CEO and lead the Company's clinical and medical functions. Her appointment is effective today, January 4, 2023. "Tami has tremendous experience across a range of therapeutic areas and drug development modalities," said Philip Serlin, Chief Executive Officer of BioLineRx.
- Appointment adds diverse commercial experience in new product planning, commercialization strategies and launch readiness spanning 13 career launches, including specific expertise in hematopoietic stem cell mobilization - TEL AVIV, Israel, June 16, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has appointed biopharmaceutical veteran executive Holly W. May as its Chief Commercial Officer. In this newly created role, based in the U.S., Ms. May will be responsible for the commercial planning, positioning and launch oversight for Motixafortide in the stem cell mobilization
Submission status for BIOLINERX, LTD.'s drug APHEXDA (ORIG-1) with active ingredient MOTIXAFORTIDE has changed to 'Approval' on 09/08/2023. Application Category: NDA, Application Number: 217159, Application Classification: Type 1 - New Molecular Entity
SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)
SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)
SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC – – BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion – – Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases – – BioLineRx will
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel, Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2024 on Monday, November 25, 2024, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can
- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60% by end of Q4 - - Doubled the number of centers ordering APHEXDA during the second quarter - - Entered into clinical trial agreement with St. Jude Children's Research Hospital to evaluate motixafortide for hematopoietic stem cell mobilization for gene therapies in sickle cell disease - - Management to host conference call today, August 15, at 8:30 am EDT - TEL AVIV, Israel, Aug. 15, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company purs
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC – – BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion – – Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases – – BioLineRx will
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel, Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2024 on Monday, November 25, 2024, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can
- Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle - - Data from proof-of-concept study shows that motixafortide was safe and well tolerated - - Oral presentation at ASH 2024 on Saturday, December 7, 2024 in San Diego, California - TEL AVIV, Israel and WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that an abstract including the initial results from a Phase
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.
HC Wainwright reiterated coverage of BioLineRx with a rating of Buy and set a new price target of $19.00 from $22.00 previously
HC Wainwright resumed coverage of BioLineRx with a rating of Buy
HC Wainwright & Co. reiterated coverage of BioLine Rx with a rating of Buy and set a new price target of $19.00 from $22.00 previously
6-K - BioLineRx Ltd. (0001498403) (Filer)
424B5 - BioLineRx Ltd. (0001498403) (Filer)
6-K - BioLineRx Ltd. (0001498403) (Filer)